AltaValve TMVR Device Delivers Lasting Relief for Severe Mitral Regurgitation at 1 Year
A novel transcatheter mitral valve replacement system shows sustained valve performance and low complications at 1 year in early trial data.
Summary
A new heart valve replacement device called AltaValve is showing strong early results for people with severe mitral regurgitation, a condition where the heart's mitral valve leaks blood backward. In a small early feasibility study of 30 patients, nearly all had little to no leakage after the procedure, and those benefits held up at the 1-year mark. Unlike older devices, AltaValve is designed to avoid blocking a critical outflow tract in the heart, making it suitable for more patients including those with complex anatomy. The device uses atrial fixation rather than anchoring into heart structures, reducing a key risk. A larger 450-patient pivotal trial is now enrolling across the US, Europe, and Canada.
Detailed Summary
Mitral regurgitation is one of the most common heart valve disorders, causing the mitral valve to leak and forcing the heart to work harder. Severe cases significantly raise the risk of heart failure, reduced quality of life, and premature death. For patients who are poor surgical candidates, transcatheter options are critical — but existing devices have major anatomical limitations that exclude many patients. The AltaValve system was designed specifically to address these gaps.
In an early feasibility study presented at the SCAI 2026 annual meeting, 30 patients with severe mitral regurgitation received the AltaValve transcatheter mitral valve replacement. After implantation, 29 of 30 patients showed no or trace regurgitation. At 1 year, 22 patients maintained that improvement, with mitral valve gradients rising modestly from 2.5 to 4.0 mm Hg — a clinically acceptable change. Left ventricular outflow tract diameter and gradient remained stable, a key safety signal.
What sets AltaValve apart is its atrial fixation design. Most competing systems anchor rigidly into subvalvular structures, increasing the risk of left ventricular outflow tract obstruction — a potentially life-threatening complication. AltaValve's annular ring avoids active attachment to native mitral or ventricular structures, and its design accommodates patients with large annuli, complex anatomy, and mitral annular calcification, groups historically excluded from transcatheter repair.
For health-conscious adults and clinicians, this matters because mitral regurgitation often goes undertreated in high-risk patients who cannot tolerate open surgery. A durable, less invasive option with broader anatomical eligibility could meaningfully extend healthspan and reduce heart failure progression in an aging population.
Important caveats apply. This is a small, non-randomized early feasibility study of just 30 patients. The pivotal ATLAS trial enrolling 450 patients is still ongoing and not expected to complete for several years. Long-term durability beyond 1 year and comparative effectiveness against surgery or other devices remain unknown.
Key Findings
- 29 of 30 patients had no or trace mitral regurgitation immediately after AltaValve implantation
- Valve performance sustained at 1 year with no increase in left ventricular outflow tract obstruction
- AltaValve's atrial fixation design expands eligibility to patients with complex mitral anatomy and calcification
- Mitral valve gradients rose modestly from 2.5 to 4.0 mm Hg — within acceptable clinical range at 1 year
- Pivotal 450-patient ATLAS trial now enrolling; 5-year follow-up planned for early feasibility cohort
Methodology
This is a meeting coverage news report summarizing an early feasibility study (n=30) presented at the SCAI 2026 annual meeting. The source, MedPage Today, is a credible peer-reviewed medical news outlet. Evidence is preliminary — single-arm, non-randomized, small sample — and has not yet been published in full peer-reviewed form.
Study Limitations
The study enrolled only 30 patients with no control group, limiting generalizability and causal conclusions. Attrition from 29 to 22 patients with favorable outcomes at 1 year warrants scrutiny. Full peer-reviewed publication and completion of the ATLAS pivotal trial are needed before clinical adoption can be broadly recommended.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.